Our molecular analyses of Trim24COE metaplastic carcinosarcoma tumors nominated c-MET receptor tyrosine kinase, an upstream activator of PI3K/AKT/mTOR pathways, as a potential therapeutic target. The gene discussed is MTOR; the disease is carcinosarcoma.